Access Keys:
Skip to content (Access Key - 0)

Center For Cancer Research DCEG National Cancer Institute

Center of Excellence in HIV/AIDS & Cancer Virology

 

The Center of Excellence in HIV/AIDS & Cancer Virology, NCI

Despite significant advances in treatment, the number of newly diagnosed HIV-infected adults and children rose globally from ~3.9 million in 2004 to 4.3 million in 2006, and the number of deaths from ~2.7 million to 2.9 million over the same period. Moreover, the initial success of highly active antiretroviral therapy (HAART) in reducing viral burden is now threatened by the rapid emergence of drug-resistant virus.  Approximately one of every five human cancers is caused by infectious agents with an estimate of 1.9 million cases per year worldwide. Of these cancers, approximately 70% are caused by viruses such as human papillomavirus, hepatitis virus types B and C, Epstein-Barr virus, human herpesvirus 8, and human T cell leukemia/lymphoma virus. Recent evidence also suggests that the increased life expectancy of HIV-infected individuals on HAART may enhance the risk of developing both AIDS-defining and non-defining cancers.  The mission of the Center of Excellence in HIV/AIDS and Cancer Virology (CEHCV), established within the NCI's Intramural Research Program, is to facilitate and rapidly communicate advances in the discovery, development and delivery of antiviral and immunologic approaches for the prevention and treatment of HIV infection, AIDS-related malignancies and cancer-associated viral diseases.  Toward this end, NCI research on AIDS, HIV and HTLV has resulted in 488 new invention reports, 1043 patents, and 246 licenses, including didanosine (Videx), ddI generics, ddC (Hivid), and darunavir (Prestiva).

To learn about recent advances by Center researchers, click on the images above.
To learn more about the Center, view our brochure.          

Special Notices/Announcements

 

HIV Drug Resistance Program Conference: Host Factors and Cofactors in HIV Infection
Date: Tuesday, February 25, 2014 (rescheduled from October 16, 2013 due to the government shutdown)
Time: 1:00 to 5:35 p.m.
Location: National Cancer Institute at Frederick, Building 549 Conference Center Auditorium, Frederick, Maryland
Conference website: http://ncifrederick.cancer.gov/Events/hivdrug/ 
 
The HIV Drug Resistance Program Conference: Host Factors and Cofactors in HIV Infection will be held at the National Cancer Institute (NCI) campus in Frederick, Maryland on February 25, 2014 from 1:00 to 5:35 p.m. The registration deadline has been extended to February 18th due to weather delays.  Registration is free, but pre-registration is necessary as seating is limited.  Online registration can be found at http://ncifrederick.cancer.gov/Events/hivdrug/register.asp 
 
The HIV Drug Resistance Program, Center for Cancer Research (CCR) is sponsoring this conference with support from the CCR Center of Excellence in HIV/AIDS & Cancer Virology and the NCI Office of HIV and AIDS Malignancy to showcase the latest findings on host factors and cofactors in HIV infection.  Understanding the interplay of HIV with both positively and negatively restricting cellular proteins, as well as the influence of cofactors in the etiology of HIV infection, will lead to new insights into the mechanisms involved in the pathogenesis of HIV disease.
 
Invited speakers in the outstanding program include Michael Emerman (Fred Hutchinson Cancer Research Center), John Guatelli (University of California San Diego and the VA San Diego Healthcare System), Welkin Johnson (Boston College), Jacek Skowronski (Case Western Reserve University), and Yong Xiong (Yale University).  In addition to research presentations by these distinguished scientists, the conference will conclude with a round-table discussion addressing future developments and opportunities for antiviral strategies and insights into novel mechanisms of carcinogenesis.  
 
Please mark February 25, 2014 on your calendar for this exciting event and forward this email to colleagues.  You can also download or print a copy of the conference flyer at http://home.ncifcrf.gov/hivdrp/DRPconference_25February2014.pdf 
  
Please note:  If you already registered for the conference when it was originally scheduled for October 16, 2013, you do not need to register again. 
 
For conference-related questions, please contact Heather Leonard at heather.leonard2@nih.gov.  
 
Individuals with disabilities who need sign language interpreters and/or reasonable accommodation to participate in this conference should contact Heather Leonard at heather.leonard2@nih.gov or the Federal TTY Relay at 1-800-877-8339 at least 5 days in advance of the event.

Current jobs in the CCR

 

 

 

 

Added by Fox, Susan (NIH/NCI) [E] , last edited by Beutler, John (NIH/NCI) [E] on Feb 19, 2014 15:52